Page 171 - Access Program News Today

/PRNewswire/ -- The "Alopecia Areata - U.S Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.coms offering....

Scientists and leaders from across Belize met at the Water Quality and Marine Pollution Workshop on June 27, 2023, at Radisson Fort George Hotel in Belize City, to share their ideas and develop next steps to tackle ocean pollution and support a healthy marine environment. At the event, hosted by the Department of the Environment (DOE), experts shared current monitoring

BAR HARBOR — Town native Isaac Steiner is passionate about cooking flavorful, artful ramen from scratch and he has always dreamed of owning his own restaurant. So when he returned

Clinical outcomes in ED visits and epinephrine autoinjector use among other indicators have revealed racial, ethnic and socioeconomic differences in prevalence of food allergies among children and adults. Published in JAMA Network Open, researchers found that rates of food allergy included 10.5% among Asian individuals, 10.6% among Hispanic individuals, 10.6% among Black individuals and 9.5%

The FDA has issued a complete response letter to the new drug application seeking the approval of ADX-2191 for the treatment of patients with primary vitreoretinal lymphoma.

Deadline: 10-Jul-23 The U.S. Embassy Yerevan, of the U.S. Department of State, announces an open competition for organizations to submit applications to

By Will Feuer Aldeyra Therapeutics said it has received a complete response letter from the U.S. Food and Drug Administration that said there was a lack of...

Biotechnology company Aldeyra Therapeutics, Inc. (ALDX) announced Wednesday the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the 505(b)(2) New Drug Application (NDA) of ADX-2191 (methotrexate for injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (PVRL).

Based on U.S. Food & Drug Administration (FDA) Determination of Lack of Adequate and Well Controlled Investigations in the Scientific Literature, Complete Response Letter Received for New Drug Application (NDA) of ADX-2191 (methotrexate injection, USP) for the Treatment of Primary Vitreoretinal Lymphoma (PVRL) Due to Shortage of Methotrexate, Lack of Approved Therapy for PVRL, and Inbound Requests for ADX-2191, Expanded Access Program Planned to be Discussed with FDA

The digital biomarkers company has partnered with Beacon Biosignlas, a computational neurodiagnostics company to launch a clinical trial investigate the integration of Beacon’s at-home electroencephalogram (EEG) into Koneksa’s neuroscience solution toolkit.